Fluid Shifts in Space: The Hidden Medical Challenge of Interplanetary Travel

Gravity Is a Medical Device

We don't think of gravity as medicine. But our bodies have been calibrated to it for millions of years. Every fluid distribution system in the human body — blood, lymph, cerebrospinal fluid — has been tuned by evolution to function under 1G.

Remove that constant, and the tuning breaks.

Within hours of entering microgravity, approximately 2 liters of fluid shift from the lower body toward the head and upper torso. Blood pools in the thorax. Facial puffiness develops. Nasal congestion becomes chronic. These are the familiar, cosmetic symptoms astronauts joke about.

The less-discussed consequences are serious.

Intracranial Pressure and Vision Loss

The most alarming discovery of the last decade in space medicine is Spaceflight-Associated Neuro-ocular Syndrome (SANS). More than 70% of astronauts on long-duration missions show measurable changes to their vision — some permanent.

The mechanism is now understood to involve elevated intracranial pressure (ICP) caused by the cephalad fluid shift. As fluid accumulates around the brain, pressure increases. That pressure transfers through the optic nerve sheath, flattening the posterior globe of the eye and causing hyperopic (farsighted) shifts in vision.

For a 6-month ISS mission, this is manageable. For an 18-month Mars transit, it becomes a potentially mission-ending medical event.

Why Current Monitoring Falls Short

Measuring ICP today requires either a lumbar puncture (invasive, impractical in-flight) or expensive imaging equipment. Neither is viable on a spacecraft.

Indirect methods — measuring optic nerve sheath diameter via ultrasound, monitoring jugular venous pressure — exist but require trained operators and bulky hardware.

There is currently no wearable, continuous, non-invasive ICP proxy monitor available for spaceflight.

Mica1's Fluid-Shift Detection Mode

This is the problem Mica1's fluid-shift mode is designed to address.

Using a combination of bioelectrical impedance analysis (BIA), photoplethysmography (PPG), and accelerometer-derived posture data, Mica1 constructs a continuous proxy model of fluid distribution changes. We don't claim to measure ICP directly — that would require intracranial access. But we can track the peripheral and thoracic fluid redistribution that correlates with ICP changes, and flag anomalies that warrant clinical attention.

The model runs entirely on-device. No network. No cloud. Because in deep space, there is no cloud.

The Broader Challenge

Fluid-shift monitoring is one mode of seven in Mica1. But in many ways, it represents the hardest and most important one — because it is the mode that doesn't exist yet in any affordable, wearable form.

We are building it from first principles, in Xi'an, with a small team, on a sub-$20 BOM target.

That constraint isn't a limitation. It's a design philosophy: the tools of space medicine should not cost as much as a spacecraft.

Further Reading

• NASA Human Research Program — SANS Evidence Report (2022)
• Wostyn et al., "Increased Subdural Space as a Possible Mechanism for Spaceflight-Associated Neuro-Ocular Syndrome" — Ophthalmic Research (2018)
• Marshall-Goebel et al., "Assessment of Jugular Venous Blood Flow Stasis and Thrombosis During Spaceflight" — JAMA Network Open (2019)

---

Nezaira is developing Mica1, a 7-mode wearable health monitor. Contact us at contact@nezaira.com.